An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
News|Slideshows|April 20, 2015
PCV13: Effective Against First-Episode CAP in Older Adults
Author(s)Leah Lawrence
The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.
Advertisement
Advertisement
Related to this article
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
Advertisement
Advertisement
Trending on Patient Care Online
1
New CKD Tool Could Simplify Risk Assessment in Primary Care
2
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
3
Nearly 80% of Women May Not Initiate Menopause Hormone Therapy: A Q&A With Intira Sriprasert, MD, PhD
4
Elinzanetant Reduced Menopausal VMS Frequency by ≥50% in 67% of Women at Week 12: TMS 2026
5